Cemacabtagene ansegedleucel is under clinical development by Allogene Therapeutics and currently in Phase II for Relapsed Chronic Lymphocytic Leukemia (CLL). According to GlobalData, Phase II drugs for Relapsed Chronic Lymphocytic Leukemia (CLL) have a 29% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Cemacabtagene ansegedleucel’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Cemacabtagene ansegedleucel overview
Cemacabtagene Ansegedleucel (Cema-Cel, Previously ALLO-501A) is under development for the treatment of diffuse large B-cell Lymphoma, marginal zone B-cell Lymphoma, primary mediastinal B-cell Lymphoma, r/r chronic lymphocytic leukemia (CLL) and follicular lymphoma. The drug candidate is an anti-CD19 Allogeneic CAR T (AlloCAR T) therapy in which a T cell receptor gene is knocked out to avoid GvHD and the CD52 gene is knocked out to render the drug resistant to anti-CD52 antibody treatment which can be used to suppress the host immune system. It is administered by intravenous route of administration.
Allogene Therapeutics overview
Allogene Therapeutics is a clinical-stage biotechnology company that develops allogeneic T-cell (CAR T) therapies for cancer. The company’s pipeline product includes ALLO-501, ALL0-501A, ALL0-316, ALL0-819, ALL0-605 and ALL0-715. Its ALL0-501 and ALL0-501A an off-the-shelf allogeneic CAR T therapy candidates for the treatment of hematological malignancies, CD70 and DLL3 for solid tumors and ALLO-647, an anti-CD52 monoclonal antibody used as lymphodepleting agent. Allogene Therapeutics develops products in the therapeutic areas of cancers and solid tumors. It collaborates with other companies for the research and development of immuno-oncology therapies. Allogene Therapeutics is headquartered in South San Francisco, California, the US.
For a complete picture of Cemacabtagene ansegedleucel’s drug-specific PTSR and LoA scores, buy the report here.